Biogenric Publishers Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -51.61%
(FY 2023)
- Profit -143.09%
(FY 2023)
- Ebitda -48.97%
(FY 2023)
- Net Worth -12.20%
(FY 2023)
- Total Assets 21.33%
(FY 2023)
About Biogenric Publishers
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Suryateja Gunti and Harshavardhani Pedavalli serve as directors at the Company.
- CIN/LLPIN
U73100TG2020PTC140272
- Company No.
140272
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 May 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Biogenric Publishers?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suryateja Gunti  | Director | 20-Sep-2021 | Current |
| Harshavardhani Pedavalli | Director | 07-May-2020 | Current |
Financial Performance of Biogenric Publishers.
Biogenric Publishers Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 51.61% decrease. The company also saw a substantial fall in profitability, with a 143.09% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biogenric Publishers?
Unlock access to Biogenric Publishers's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Celebrites World Private LimitedActive 3 years 11 monthsSuryateja Gunti and Harshavardhani Pedavalli are mutual person
- Trig It Solutions Private LimitedActive 3 years 9 months
Suryateja Gunti and Harshavardhani Pedavalli are mutual person
- Audire Business Solutions Private LimitedActive 3 years 8 months
Harshavardhani Pedavalli is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biogenric Publishers?
Biogenric Publishers has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biogenric Publishers, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biogenric Publishers's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
